Literature DB >> 12888133

Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies.

Harm Wienbergen1, Anselm Kai Gitt, Rudolf Schiele, Claus Juenger, Tobias Heer, Christina Meisenzahl, Peter Limbourg, Claus Bossaller, Jochen Senges.   

Abstract

In clinical practice, we found no significant difference between atorvastatin therapy or other statin therapies in the clinical outcomes of patients with acute coronary syndromes receiving clopidogrel therapy. In patients receiving atorvastatin therapy, clopidogrel therapy was associated with a significant decrease in mortality and stroke during univariate analysis and a moderate trend of reduced mortality and stroke without statistical significance in the multivariate analysis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12888133     DOI: 10.1016/s0002-9149(03)00626-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  20 in total

Review 1.  Central role of the P2Y12 receptor in platelet activation.

Authors:  Robert T Dorsam; Satya P Kunapuli
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

2.  [Interaction of statins with clopidogrel].

Authors:  W Von Scheidt
Journal:  Internist (Berl)       Date:  2004-03       Impact factor: 0.743

Review 3.  Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John W Eikelboom; Jack Hirsh; Frederick A Spencer; Trevor P Baglin; Jeffrey I Weitz
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 4.  Old and new molecular mechanisms associated with platelet resistance to antithrombotics.

Authors:  Antonio J López Farré; Juan Tamargo; Petra J Mateos-Cáceres; Luís Azcona; Carlos Macaya
Journal:  Pharm Res       Date:  2010-07-14       Impact factor: 4.200

5.  Clopidogrel and the possibility of drug-drug interaction in primary health care.

Authors:  Inga Urtane; Aleksandra Aitullina; Katrina Pukite
Journal:  J Young Pharm       Date:  2013-03-07

6.  Understanding clopidogrel efficacy in the presence of cytochrome P450 polymorphism.

Authors:  Jacques Turgeon; Chantal Pharand; Véronique Michaud
Journal:  CMAJ       Date:  2006-06-06       Impact factor: 8.262

Review 7.  CYP-mediated pharmacologic interference with optimal platelet inhibition.

Authors:  Thomas Cuisset; Jacques Quilici
Journal:  J Cardiovasc Transl Res       Date:  2013-01-12       Impact factor: 4.132

8.  Concomitant use of clopidogrel and statins and risk of major adverse cardiovascular events following coronary stent implantation.

Authors:  Morten Schmidt; Martin B Johansen; Michael Maeng; Anne Kaltoft; Lisette O Jensen; Hans-Henrik Tilsted; Hans E Bøtker; John A Baron; Henrik Toft Sørensen
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

Review 9.  Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4.

Authors:  Wei C Lau; Paul A Gurbel
Journal:  Pharm Res       Date:  2006-10-24       Impact factor: 4.200

10.  Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease.

Authors:  Seung-Pyo Lee; Jung-Won Suh; Kyung Woo Park; Hae-Young Lee; Hyun-Jae Kang; Bon-Kwon Koo; In-Ho Chae; Dong-Ju Choi; Seung-Woon Rha; Jang-Whan Bae; Myeong-Chan Cho; Taek-Geun Kwon; Jang-Ho Bae; Hyo-Soo Kim
Journal:  Trials       Date:  2010-08-24       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.